Analytical Data
-
Gene name
CCNE2
- Application
-
Alternative Names
CCNE2; G1/S-specific cyclin-E2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O96020
-
Expression Region
1-404aa
-
AA Sequence
MSRRSSRLQA KQQPQPSQTE SPQEAQIIQA KKRKTTQDVK KRREEVTKKH QYEIRNCWPP VLSGGISPCI IIETPHKEIG TSDFSRFTNY RFKNLFINPS PLPDLSWGCS KEVWLNMLKK ESRYVHDKHF EVLHSDLEPQ MRSILLDWLL EVCEVYTLHR ETFYLAQDFF DRFMLTQKDI NKNMLQLIGI TSLFIASKLE EIYAPKLQEF AYVTDGACSE EDILRMELII LKALKWELCP VTIISWLNLF LQVDALKDAP KVLLPQYSQE TFIQIAQLLD LCILAIDSLE FQYRILTAAA LCHFTSIEVV KKASGLEWDS ISECVDWMVP FVNVVKSTSP VKLKTFKKIP MEDRHNIQTH TNYLAMLEEV NYINTFRKGG QLSPVCNGGI MTPPKSTEKP PGKH
-
Molecular Weight
46.7 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNE2, or Cyclin E2, is a member of the cyclin family that plays a crucial role in cell cycle regulation, particularly in the transition from the G1 phase to the S phase. Its dysregulation has been implicated in various cancers, making it a key target for research in cancer biology and therapeutic interventions. The study of CCNE2 recombinant proteins has gained attention as it provides insights into the structure-function relationships of this cyclin, facilitating the understanding of its regulatory mechanisms within the cell cycle. Researchers utilize recombinant DNA technology to express CCNE2 in various host systems, allowing for the production of functional, purified protein that can be used in biochemical assays and structural studies. These investigations aim to elucidate the interaction of CCNE2 with cyclin-dependent kinases (CDKs) and other cell cycle regulators, shedding light on its role in oncogenesis and potential as a biomarker or therapeutic target in cancer treatment. Additionally, by exploring the post-translational modifications and interaction partners of CCNE2, scientists hope to identify novel regulatory pathways that could be exploited for therapeutic advantages. Overall, the study of CCNE2 recombinant proteins is pivotal for advancing our understanding of cell cycle control and its implications in cancer progression.
